PXAI
v8.42
Feed
Viral
World
Politics
Technology
Daily Briefing
Sources
|
ToS
Version History
Version
Description
Date
8.42
[ADDED SOURCE REGISTRY LIST VIEW]
04/03/2026 16:19
8.41
[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]
04/03/2026 16:11
8.40
[TRANSLATED FRONTEND TO US ENGLISH]
04/03/2026 16:10
8.41
[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]
04/03/2026 15:50
8.41
[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]
04/03/2026 15:46
8.40
[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]
04/03/2026 15:40
8.39
[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]
04/03/2026 15:38
8.38
[TRANSLATED SOURCES VIEW TO US ENGLISH]
04/03/2026 15:01
8.37
[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]
04/03/2026 14:58
8.67
[MANUAL OVERRIDE OF GREEK MENU ITEMS]
04/03/2026 13:36
8.66
[NGINX OPTIMIZED MENU FIX]
04/03/2026 13:33
8.65
[FIXED GREEK MENU ITEMS]
04/03/2026 13:32
8.60
[MENU & UI LOCALIZATION TO US ENGLISH]
04/03/2026 13:30
8.50
[FULL TRANSLATION TO US ENGLISH]
04/03/2026 13:27
9.75
[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]
26/02/2026 14:44
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts
Chronological Source Flow
Back
AI Fusion Summary
Sagimet Biosciences (SGMT) has a consensus Moderate Buy rating from 11 analysts, with 8 buys, 2 holds, 1 sell; average 12‑month target $26.25. Recent upgrades include Wall Street Zen (sell→hold) and Barclays (equal weight).
#Sagimet Biosciences
#SGMT
#Moderate Buy
#analyst ratings
#price target
#Wall Street Zen
#Barclays
#biotech
02/04 09:15
defenseworld.net
4 Πηγές
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts
Sagimet Biosciences
SGMT
Moderate Buy
analyst ratings
price target
Wall Street Zen
02/04 09:51
defenseworld.net
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Buy” from Analysts
COMPANIES
POLITICS
CONSENSUS RATING ARTICLES
02/04 11:32
defenseworld.net
Spire Global, Inc. (NYSE:SPIR) Receives Average Rating of “Moderate Buy” from Brokerages
POLITICS
COMPANIES
CONSENSUS RATING ARTICLES
02/04 11:49
defenseworld.net
Omada Health, Inc. (NASDAQ:OMDA) Receives Average Rating of “Moderate Buy” from Analysts
POLITICS
COMPANIES
CONSENSUS RATING ARTICLES
Comments
Loading...
Send
Dev Changelog
v8.42
No logs found in database.
0
Display Settings
Size
Aa
Brightness
Theme
Dark
Comments